Taysha Gene Therapies Inc 2025年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember 30,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ___________ to ___________Commission File Number:001-39536 Taysha Gene Therapies, Inc.(Exact Name of Registrant as Specified in its Charter) Delaware84-3199512( State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)3000 Pegasus Park DriveSte 1430Dallas,Texas75247(Address of principal executive offices)(Zip Code)Registrant’s telephone number, including area code: (214)612-0000 Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon stock, par value $0.00001 per shareTSHAThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of November 4, 2025, the registrant had273,919,373shares of common stock, $0.00001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (Unaudited)1Balance Sheets1Statements of Operations2Statements of Other Comprehensive Loss3Statements of Stockholders’ Equity4Statements of Cash Flows6Notes to Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations29Item 3.Quantitative and Qualitative Disclosures About Market Risk48Item 4.Controls and Procedures49PART II.OTHER INFORMATIONItem 1.Legal Proceedings50Item 1A.Risk Factors50Item 2.Unregistered Sales of Equity Securities and Use of Proceeds55Item 3.Defaults Upon Senior Securities55Item 4.Mine Safety Disclosures55Item 5.Other Information55Item 6.Exhibits56Signatures57 Taysha Gene Therapies, Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share data)(Unaudited) Taysha Gene Therapies, Inc.Condensed Consolidated Statements of Operations(in thousands, except share and per share data)(Unaudited) Taysha Gene Therapies, Inc.Condensed Consolidated Statements of Comprehensive Loss(in thousands, except share and per share data)(Unaudited) Taysha Gene Therapies, Inc.Condensed Consolidated Statements of Stockholders’ Equity(in thousands, except share data)(Unaudited) Taysha Gene Therapies, Inc.Condensed Consolidated Statements of Stockholders’ Equity(in thousands, except share data)(Unaudited) Taysha Gene Therapies, Inc.Condensed Consolidated Statements of Cash Flows(in thousands)(Unaudited) Taysha Gene Therapies, Inc.Notes to Condensed Consolidated Financial Statements(Unaudited) Note 1—Organization and Description of Business Operations Taysha Gene Therapies, Inc. (the “Company” or “Taysha”) was originally formed under the laws of the State of Texas onSeptember 20, 2019. Taysha converted to a Delaware corporation onFebruary 13, 2020, which had no impact to the Company’s parvalue or issued and authorized capital structure. Taysha is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenicdiseases of the central nervous system. Sales Agreement On October 5, 2021, the Company entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (f/k/aSVB Leerink LLC) and Wells Fargo Securities, LLC (collectively, the “Sales Agents”), pursuant to which the Company may issueand sell, from time to time in its sole discretion, shares of its common stock having an aggre